Eloxx Pharmaceuticals, Inc. (ELOX) Stock Forecast
ELOX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $38.25 average of analyst targets
- Upside to target
- +193.6% from the latest close
- Next earnings
- November 10, 2026
- 52-week range
- $10.95 – $20.98
ELOX analyst ratings
5 analystsNumber of analysts at each rating.
ELOX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ELOX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.58 | −$0.65 | −$0.51 | — | — | 3 |
| Current fiscal year (2026) | −$2.23 | −$2.85 | −$0.99 | −$5.39 | +58.6% | 4 |
| Next fiscal year (2027) | −$2.55 | −$3.61 | −$1.83 | −$2.23 | −14.2% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ELOX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
ELOX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ELOX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.65 | −$0.61 | −$0.58 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | −$2.47 | −$2.85 | −$2.10 | −$2.23 | — | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | −$3.61 | −$2.72 | −$2.72 | −$2.55 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
What analysts expect from ELOX
5 analysts cover Eloxx Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $38.25, 193.6% above the latest close of $13.03. Analysts expect earnings of −$2.23 per share for 2026, +58.6% from a year earlier. For 2027 the average estimate is −$2.55 per share.
Related: ELOX income statement, ELOX key metrics, ELOX chart. See the ELOX stock overview for the latest quote and news.
ELOX forecast FAQ
What is Eloxx Pharmaceuticals's price target?
The average analyst price target for Eloxx Pharmaceuticals is $38.25, 193.6% above the latest close of $13.03.
Is Eloxx Pharmaceuticals a buy, hold or sell?
Of 5 analysts covering Eloxx Pharmaceuticals, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eloxx Pharmaceuticals's EPS forecast?
Analysts forecast −$2.23 per share for 2026 (range −$2.85 to −$0.99); for 2027 the estimate is −$2.55.
When does Eloxx Pharmaceuticals report earnings?
Eloxx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 10, 2026.